OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Experimental & Clinical Cancer Research is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells	327
The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors	273
Correction: Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway	257
Retraction Note: Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells	251
Correction: ZEB1-mediated biogenesis of circnipbl sustains the metastasis of bladder cancer via Wnt/β-catenin pathway	244
Retraction Note: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells	233
CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma	191
Targeting homologous recombination deficiency in uterine leiomyosarcoma	188
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer	188
Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer	166
LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma	154
FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer	152
The RP11-417E7.1/THBS2 signaling pathway promotes colorectal cancer metastasis by activating the Wnt/β-catenin pathway and facilitating exosome-mediated M2 macrophage polarization	147
Targeting FAM83D triggers tumor cell senescence via cGAS-STING signaling activation and reprograms TAMs to combat glioma	145
Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models	145
Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer	144
The importance of being CAFs (in cancer resistance to targeted therapies)	129
HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma	122
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma	120
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway	114
Correction: circular RNA circATP9A promotes non-small cell Lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization	114
Novel APLNR antagonist candesartan induces tumor vascular normalization through ROS/cGAS/STING axis and augmented sunitinib response in breast cancer	113
M2 macrophage-secreted KYNU promotes stemness remodeling and malignant behavior in endometrial cancer via the SOD2-mtROS-ERO1α-UPRER axis	110
TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity	107
tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma	106

cGAS-STING pathway regulated by spatiotemporal heterogeneity of tumor microenvironment and precision therapy strategies in lung cancer	104
The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression	102
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response	101
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer	100
Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG	99
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance	99
SEC23A confers ER stress resistance in gastric cancer by forming the ER stress-SEC23A-autophagy negative feedback loop	98
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer	96
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer	94
The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint	94
The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway	94
TWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitors	91
Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer	90
Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis	90
Circulating CD137⁺Treg cells and LOX-1⁺PMN-MDSCs as biomarkers of immunotherapy resistance in (R/M) HNSCC patients	88
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma	86
CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect	84
CCNY-mediated phosphorylation and TET2-BACH1-driven DNA demethylation activate PRC1 to augment NSCLC progression	84
LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2	83
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer	82
Plasma-derived extracellular vesicles miR-335–5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma	82
Correction: Deliberation concerning the role of M1-type macrophage subset in oral carcinogenesis	82
Inhibition of RACGAP1 sensitizes triple-negative breast cancer cells to ferroptosis by regulating CPT1A-dependent fatty acid metabolism	82
Correction: LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond	81
Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer	81
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade	81
CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer	81
Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening	81
USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer	80
NRGN inhibits CD8⁺ T cell effector function by downregulating MHC-I expression through the FMR1–IRF8 axis in hepatocellular carcinoma	77
CSRP2 promotes the glioblastoma mesenchymal phenotype via p130Cas-mediated NF-κB and MAPK pathways	77
Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop	76
Mechanism of cancer-associated fibroblast-driven thyroid cancer dedifferentiation via the ZFP57-PKM2 axis-mediated lactate secretion and therapeutic intervention with resveratrol	76
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth	75
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth	75
The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution	74
Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers	74
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis	74
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma	73
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?	73
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment	73
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models	73
Targeting the CCL5/CCR5 axis in tumor-stromal crosstalk to overcome cisplatin resistance in neuroendocrine prostate cancer	72
Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics	72
Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair	72
C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer	71
The KLF16/MYC feedback loop is a therapeutic target in bladder cancer	71
Unbiased profiling of translational landscape reveals TNFR2 as a translation-dependent vulnerability in colorectal cancer	71